Plain-English translation of NCT07230223 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing Ev.FV, a new treatment made from tiny packages derived from stem cells, to see if it can help heal chronic wounds in people with dystrophic epidermolysis bullosa (a severe genetic condition where skin blisters easily and wounds don't heal well). The treatment works by delivering healing molecules directly to damaged skin, rather than using live cells. Researchers hope this medication will reduce inflammation, help skin cells regrow, and repair the connection between skin layers.
Dystrophic epidermolysis bullosa is a devastating genetic disease where people's skin lacks a critical protein called collagen VII, making wounds extremely difficult to heal. Current treatment options are very limited, so this trial exists to test whether this new cell-derived treatment could offer patients a real biological option for healing chronic wounds and improving their quality of life.
You likely qualify if…
You likely don't qualify if…
As a participant, you would receive the Ev.FV treatment applied to your chronic wounds as part of the study protocol. You would attend visits to the clinical center where your wounds would be examined and monitored for healing progress and safety. The study involves about 20 participants total and is designed to evaluate both whether the treatment is safe and whether it actually helps wounds heal better.
AI-generated summary from trial data · Sep 24, 2026 · Not medical advice
Iran